The Albany Gazette - Study Reveals Menstrual Cycle Impact on Type 1 Diabetes Insulin Needs

Women with Type 1 diabetes experience significant, predictable fluctuations in their blood sugar regulation and insulin needs throughout their menstrual cycles, yet current automated medical devices largely ignore these patterns. This gap between physiological reality and technological capability was highlighted by new research published in the September issue of the journal Diabetes Care.

The findings come from an observational study led by Martina Rothenbühler, Scientific Program Manager at the Diabetes Center Berne. Rothenbühler presented the data during a press conference ahead of the German Diabetes Society’s (DDG) autumn congress, scheduled for November 13 and 14 in Dresden. She warned that medical guidelines and automated insulin delivery (AID) systems fail to adequately address these gender-specific physiological changes.

The study analyzed data from 77 women with Type 1 diabetes who utilized AID systems, covering a total of 380 menstrual cycles. The researchers identified systematic variations in insulin demand, carbohydrate intake, and blood glucose levels that correlated with specific phases of the cycle.

During the early follicular phase at the start of the cycle, participants exhibited increased insulin sensitivity. Consequently, they often required less insulin than during other periods. In contrast, the mid-luteal phase saw the highest daily insulin doses and carbohydrate consumption. During this phase, insulin sensitivity drops to its lowest point, leading to higher average glucose concentrations.

The study noted that while women naturally increased their carbohydrate intake during the luteal phase, they also attempted to compensate with higher insulin doses. However, this compensation was often insufficient. The result was elevated blood sugar levels and reduced time in range (TIR) and tighter time in range (TITR) metrics.

Approximately 85 percent of the women in the study displayed these patterns, which are also observed in women without diabetes. However, significant individual deviations existed among participants. The researchers concluded that sex-specific physiology is a critical factor in blood sugar regulation that remains underrepresented in current clinical guidelines and algorithmic design.

While AID systems dynamically adjust to short-term glucose fluctuations, they rely primarily on data from the preceding days. They do not learn from or anticipate recurring cyclical changes. This limitation can lead to hyperglycemia before menstruation and an increased risk of hypoglycemia at the start of the cycle.

To manage these swings, many participants manually adjusted their insulin delivery. Some altered AID system settings or logged carbohydrates they had not actually consumed to manipulate glucose readings. While these manual interventions improved TIR values, Rothenbühler described them as stressful and exhausting for patients.

"So far, no approved system explicitly considers the menstrual cycle when controlling insulin delivery," Rothenbühler stated. She emphasized that current algorithms lack the capacity to integrate this contextual data.

To address this issue, Rothenbühler and her colleagues have initiated a follow-up study called TIMES. The trial will enroll 350 women with Type 1 diabetes who use AID systems. It aims to determine cycle phases more precisely through ovulation tests and gather additional contextual information to help develop algorithms that can better support patients through these physiological variations.

The DDG congress, where these findings were discussed, serves as a key forum for addressing such gaps in diabetes care standards. As technology advances, the medical community is increasingly calling for systems that recognize the biological realities of female patients rather than treating them as outliers.

(Y.Harris--TAG)